Compare · KVUE vs SBTX
KVUE vs SBTX
Side-by-side comparison of Kenvue Inc. (KVUE) and Silverback Therapeutics Inc. (SBTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KVUE and SBTX operate in Specialty Chemicals (Consumer Discretionary), so they compete in similar markets.
- KVUE is the larger of the two at $34.83B, about 218.8x SBTX ($159.2M).
- KVUE has hit the wire 15 times in the past 4 weeks while SBTX has been quiet.
- KVUE has more recent analyst coverage (25 ratings vs 6 for SBTX).
- Company
- Kenvue Inc.
- Silverback Therapeutics Inc.
- Price
- $18.13+0.33%
- $5.84+0.69%
- Market cap
- $34.83B
- $159.2M
- 1M return
- +5.44%
- -
- 1Y return
- -16.30%
- -
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- 2020
- News (4w)
- 15
- 0
- Recent ratings
- 25
- 6
Silverback Therapeutics Inc.
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Latest KVUE
- CFO & CAO Howlett Heather sold $66,988 worth of shares (3,700 units at $18.11), decreasing direct ownership by 11% to 29,288 units (SEC Form 4)
- SEC Form 144 filed by Kenvue Inc.
- SEC Form SD filed by Kenvue Inc.
- SEC Form 4 filed by Director Smith Jeffrey C
- SEC Form 4 filed by Director Hofstetter Sarah
- SEC Form 4 filed by Director Holden Betsy D
- SEC Form 4 filed by Director Merlo Larry J
- SEC Form 4 filed by Director Sneed Michael E
- SEC Form 4 filed by Director Prabhu Vasant M
- Group President LATAM Curado Gomes De Lemos Leonardo converted options into 24,248 shares and covered exercise/tax liability with 7,141 shares (SEC Form 4)
Latest SBTX
- SEC Form SC 13G/A filed by Silverback Therapeutics Inc. (Amendment)
- Lowenthal Richard E gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 20% to 4,126,822 units (SEC Form 4)
- SEC Form 4 filed by Karas Eric
- Tanimoto Sarina gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 24% to 3,276,854 units (SEC Form 4)
- SEC Form 4 filed by Dorsey Brian
- SEC Form 4 filed by Chakma Justin
- SEC Form 4 filed by Scott Kathleen D.
- SEC Form 4 filed by Fitzpatrick Alexander A
- SEC Form 10-Q filed by Silverback Therapeutics Inc.
- Silverback Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits